Instituto de Medicina Integral Professor Fernando Figueira

Recife, Pernambuco 50070-902

1 studies enrolling now · 4 studies all time

What they study most

Acute Lymphoblastic Leukemia (ALL), Adjuvant, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, Melanoma, NSCLC, Stage IB-IIIA, Non-Small Cell Lung Cancer, Post-surgical, Uncommon EGFR Mutations

Studies at this site

• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia — Completed